Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

NCT06828055 is registered in ClinicalTrials.gov with Viking Therapeutics, Inc. as lead sponsor.

NCT NCT06828055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06828055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
Lead sponsor
Viking Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 18, 2024
Completion date
August 15, 2025
Enrollment
280 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

weight loss